PERMAPEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Permapen, and what generic alternatives are available?
Permapen is a drug marketed by Casper Pharma Llc and is included in one NDA.
The generic ingredient in PERMAPEN is penicillin g benzathine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the penicillin g benzathine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PERMAPEN?
- What are the global sales for PERMAPEN?
- What is Average Wholesale Price for PERMAPEN?
Summary for PERMAPEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Clinical Trials: | 1 |
| DailyMed Link: | PERMAPEN at DailyMed |
Recent Clinical Trials for PERMAPEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CNS Onlus | Phase 2 |
| University of Florence | Phase 2 |
US Patents and Regulatory Information for PERMAPEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Casper Pharma Llc | PERMAPEN | penicillin g benzathine | INJECTABLE;INJECTION | 060014-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
